These four compounds were developed as inhibitors to BCR-ABL for the treatment of chronic myeloid leukaemia, but have since been found to have a number of novel kinase and non-kinase targets [50], including SRC and DDR2 [51,52]. Here, DDR2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.